AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$ABT

Abbott to spin-off nutrition into standalone business

Abbott Laboratories plans to spin off its nutrition business, which has $8.5bn in annual sales, into a standalone publicly traded company by the end of 2027. The move aims to address different investment profiles and growth strategies. Abbott's Q3 and nine-month results show a 1.3% decline in nutrition sales but a 11.9% increase in total group sales. The company recently settled lawsuits related to infant formula recalls for $385m and $670m.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott to spin-off nutrition into standalone business — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

The separation aims to give each business a clearer strategic focus, which may lead to divergent performance trajectories.

02

Market read

First‑report spin‑off announcement for a large U.S. healthcare firm, likely to affect ABT’s share price and create a new tradable entity.

03

What to watch

Potential tax advantages for shareholders and the ability of the nutrition unit to pursue faster innovation cycles.

Relevance 7/10Novelty 8/10Timing: today

Background

Abbott Laboratories (ABT) is a diversified healthcare company; the nutrition segment includes well‑known brands such as Similac and Ensure.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott announced a tax‑free spin‑off of its $8.5 bn nutrition business into a separate publicly traded company.

Expected impact

likely modest downside for ABT as the market prices in the loss of nutrition revenue

Evidence & confidence

Spin‑offs typically cause a temporary dip in the parent’s share price while the standalone unit is valued separately.

Market effects

Sector

Nutrition and infant‑formula segment may see increased analyst coverage and potential re‑rating of peers.

Regional

U.S. healthcare sector could see slight rebalancing as investors allocate between medical devices/diagnostics and nutrition.

Global

Limited to investors tracking large‑cap healthcare stocks and spin‑off opportunities.

Counterpoint

What could challenge this read

The spin‑off could unlock value if the nutrition business outperforms expectations, suggesting a buy on the new entity.

Key entities

  • Executive
    Robert Ford

    Chairman and CEO of Abbott, announced the spin‑off.

  • Executive
    Daniel Salvadori

    Will become CEO of the new nutrition company.

Read at source← All news

StoryAbbott Laboratories to spin off its nutrition business into a standalone public company

Also covered by

3 outlets

Related articles

OCT 23
$ABTMed

StoneX reiterates Buy on Abbott Labs stock, $120 target unchanged

StoneX reiterated a Buy rating and $120 target for Abbott Labs (ABT) after Q3 results. Abbott lowered its full-year revenue guidance to 6% and adjusted EPS to $5.50-$5.55. StoneX reduced its 2026 and 2027 revenue and EPS estimates. Abbott's Q3 revenue was $13.01B, up 7%, with adjusted EPS of $1.42. The company plans to spin off its Nutrition business by 2027. Analysts have mixed reactions to the guidance changes.

investing.com1 min
OCT 23
$ABTMedAI 8/10

Abbott’s colorectal cancer test shows improved sensitivity

Abbott (NYSE: ABT) presented data at the European Society for Medical Oncology Congress showing its Oncodetect test for colorectal cancer recurrence achieved 72.2% sensitivity, outperforming its previous version. The study analyzed 279 patients, detecting additional cases with the new test. Patients with detectable ctDNA had higher recurrence risk and lower survival rates. The test is not FDA-approved and is performed at Genomic Health Inc.

investing.com2 min
OCT 23
$ABTMedAI 8/10

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott (NYSE: ABT) presented data at ESMO 2026 showing its Oncodetect® test improved sensitivity for detecting colorectal cancer recurrence by 30% compared to its previous test. The study found a 10.6-fold higher recurrence risk for patients with detectable ctDNA. Abbott aims to connect innovations across cancer care, from early detection to post-treatment monitoring.

prnewswire.com2 min
OCT 22
$ABTMed

ABT Maintained by RBC Capital -- Price Target Lowered to $125

RBC Capital maintained an 'Outperform' rating on Abbott Laboratories (ABT) but lowered its price target from $130 to $125. GuruFocus values ABT at $135.74, suggesting a 24.9% undervaluation. The company has a GF Score of 82/100, indicating strong financial health and growth potential, but insiders have sold $46.85M in shares over the past three months.

gurufocus.com2 min